chronic disease

Novo Nordisk Invests $4 Billion to Expand US Production

Ozempic producer Novo Nordisk announced plans to invest $4.1 billion to build a second fill and finishing manufacturing facility in Clayton, North Carolina, for the production of obesity and diabetes drugs.

Teva and IBM Expand e-Health Alliance

After Pharma’s Patent Cliff